Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

Sarah Huet, Etienne Paubelle, Camille Lours, Beatrice Grange, Lucien Courtois, Kaddour Chabane, Carole Charlot, Isabelle Mosnier, Thomas Simonet, Sandrine Hayette, Isabelle Tigaud, Xavier Thomas, Gilles Salles, Fabien Subtil, Pierre Sujobert

Blood (2018) 132 (8): 865–867.

https://doi.org/10.1182/blood-2018-03-840348

Published: 2018

Includes: Supplemental data

Journal Articles

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Helene Labussiere, MD, PhD, Madeleine Etienne, CRA, Marie-Pierre Fort, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Kaddour Chabane, Eric Lippert, MD, Mohamad Sobh, Pharm.M., Stephanie Dulucq, MD, Stephane Morisset, Stat., Mauricette Michallet, Francois-Xavier Mahon, MD, PhD, Gabriel Etienne, MD, PhD

Blood (2011) 118 (21): 1684.

https://doi.org/10.1182/blood.V118.21.1684.1684

Published: 2011

Journal Articles

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Hélène Labussière, MD, Sandrine Hayette, PhD, Kaddour Chabane, BSc, Marie-Claude Gagnieu, PharmD, Quoc-Hung Lê, MD, PhD, Isabelle Tigaud, MD, Joëlle Bernard, BSc, Fiorenza Barraco, MD, Jean-Pierre Magaud, MD, PhD, Mauricette Michallet, MD, PhD, Franck E Nicolini, MD, PhD

Blood (2008) 112 (11): 2643.

https://doi.org/10.1182/blood.V112.11.2643.2643

Published: 2008

Journal Articles

Detection of Twelve Nucleotides Instertion in the BCR-ABL Kinase Domain in an Imatinib-Resistant but Dasatinib-Sensitive Patient with Bi-Phenotypic Acute Leukemia.

Sandrine Hayette, PhD, Kaddour Chabane, BSc, Andrei Tchirkov, MD, PhD, Marc G Berger, MD, PhD, jean-Pierre Magaud, MD, PhD, Franck E Nicolini, MD, PhD, Olivier Tournilhac, MD, PhD

Blood (2008) 112 (11): 1615.

https://doi.org/10.1182/blood.V112.11.1615.1615

Published: 2008

Journal Articles

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Franck Nicolini, MD, PhD, Laurence Legros, MD, PhD, Lydia Roy, MD, PhD, Jean-Claude Chomel, MD, Kaddour Chabane, BSc, Sophie Ducastelle, MD, Selim Corm, MD, Mauricette Michallet, MD, PhD, Francois Guilhot, MD, Ali Turhan, MD, PhD, Sandrine Hayette, PhD

Blood (2008) 112 (11): 1103.

https://doi.org/10.1182/blood.V112.11.1103.1103

Published: 2008

Journal Articles

Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.

Jean-Michel Cayuela, Philippe Rousselot, Franck Nicolini, Daniel Espinouse, Christophe Ollagnier, M.H. Bui-Thi, Kaddour Chabane, E. Raffoux, Isabelle Tigaud, Jean-Pierre Magaud, Sandrine Hayette

Blood (2005) 106 (11): 4830.

https://doi.org/10.1182/blood.V106.11.4830.4830

Published: 2005

Journal Articles

The K247R Substitution in ABL Tyrosine Kinase Domain Is Not a Mutation Leading to Imatinib Resistance but a Polymorphism Rarely Present in CML Patients and in Normal Subjects.

Kaddour Chabane, Franck Nicolini, Jean-Michel Cayuela, Philippe Rousselot, Xavier Thomas, Annick Bertholin, Mauricette Michallet, Jean-Pierre Magaud, Sandrine Hayette

Blood (2005) 106 (11): 4831.

https://doi.org/10.1182/blood.V106.11.4831.4831

Published: 2005

Journal Articles

Hematopoietic Progenitor Cell Response to SDF-1 alpha and SDF-1 alpha Production Are Impaired in Chronic Phase Chronic Myeloid Leukemia at Diagnosis.

Thomas Prebet, MD, Kaddour Chabane, BSc, Isabelle Tigaud, MD, Eric Wattel, MD, PhD, Mauricette Michallet, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2005) 106 (11): 1384.

https://doi.org/10.1182/blood.V106.11.1384.1384

Published: 2005

NARROW

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Detection of Twelve Nucleotides Instertion in the BCR-ABL Kinase Domain in an Imatinib-Resistant but Dasatinib-Sensitive Patient with Bi-Phenotypic Acute Leukemia.

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.

The K247R Substitution in ABL Tyrosine Kinase Domain Is Not a Mutation Leading to Imatinib Resistance but a Polymorphism Rarely Present in CML Patients and in Normal Subjects.

Hematopoietic Progenitor Cell Response to SDF-1 alpha and SDF-1 alpha Production Are Impaired in Chronic Phase Chronic Myeloid Leukemia at Diagnosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only